Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | See Remarks | August 19, 2026 | August 21, 2026 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Chief Medical Officer | February 27, 2020 | March 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,592 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Sale · Disposed 1,697 · Balance 117,592 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
Verrica Pharmaceuticals Inc.
Report date February 27, 2020 · Filed March 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.81 · Expires 2030-02-26 | Direct | 55,000 |
Reported balance
After 2020-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-27 · Grant · Acquired 55,000 · Balance 55,000 F1: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 20:08 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,697 | $27.00 | $45,819.00 |
DisclosureSEC source: 0001628280-26-058420 · wk-form4_1787342879.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,592 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 6,700 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · derivative · entry 6 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,750 Underlying: Common Stock · 6,700 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. F1 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,700 | $26.08 | $174,767.49 |
DisclosureSEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · nonDerivative · entry 4 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,289 F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 6,700 | $3.64 | $24,388.00 |
DisclosureSEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 11, 2026 Filed Aug 14, 2026 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 8,300 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · derivative · entry 5 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,450 Underlying: Common Stock · 8,300 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. F1 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 11, 2026 Filed Aug 14, 2026 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 8,300 | $26.52 | $220,129.28 |
DisclosureSEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,289 F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.50 to $26.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 11, 2026 Filed Aug 14, 2026 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 8,300 | $3.64 | $30,212.00 |
DisclosureSEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 955 | $26.12 | $24,941.54 |
DisclosureSEC source: 0001628280-26-053755 · wk-form4_1785980541.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,289 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 11, 2026 Filed May 13, 2026 23:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 222 | $21.05 | $4,673.10 |
DisclosureSEC source: 0001741987-26-000004 · wk-form4_1778715752.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,244 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. Read SEC document |
| May 04, 2026 Filed May 6, 2026 22:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 684 | $23.61 | $16,149.65 |
DisclosureSEC source: 0001741987-26-000002 · wk-form4_1778105713.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,466 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 181 | $25.91 | $4,690.43 |
DisclosureSEC source: 0001628280-26-014324 · wk-form4_1772588506.xml · nonDerivative · entry 4 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,150 F4 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F6 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.71 to $26.70, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F7 · balance_after: Due to a scrivener's error on the Reporting Person's Form 4s filed since November 5, 2025, the number of shares of common stock beneficially owned by the Reporting Person reflected a discrepancy that inadvertently understated the Reporting Person's ownership by a range of 18 to 36 shares. The corrected number of shares beneficially owned is reflected in this Form 4. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,106 | $25.16 | $153,629.40 |
DisclosureSEC source: 0001628280-26-014324 · wk-form4_1772588506.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,295 F4 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $26.97 | $0.00 |
DisclosureSEC source: 0001628280-26-014324 · wk-form4_1772588506.xml · derivative · entry 5 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-02-27 F8 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014324 · wk-form4_1772588506.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,401 F3 · kind: Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 00:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 9,794 | $25.81 | $252,747.88 |
DisclosureSEC source: 0001628280-26-005571 · wk-form4_1770251397.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,651 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.58 to $26.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 00:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,675 | $25.50 | $93,706.62 |
DisclosureSEC source: 0001628280-26-005571 · wk-form4_1770251397.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,445 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 22:46 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,490 | $28.98 | $72,165.68 |
DisclosureSEC source: 0001628280-26-001241 · wk-form4_1767826005.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,120 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.77 to $29.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 23:12 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,156 | $29.39 | $33,974.03 |
DisclosureSEC source: 0001628280-26-000209 · wk-form4_1767395540.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,610 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020. F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $29.0829 to $29.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 23:12 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 541 | $28.81 | $15,586.21 |
DisclosureSEC source: 0001628280-26-000209 · wk-form4_1767395540.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,766 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020. F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.08 to $29.08, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001741987-25-000010 · wk-form4_1766012033.xml · derivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,750 Underlying: Common Stock · 11,500 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F4 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 11,500 | $28.94 | $332,851.40 |
DisclosureSEC source: 0001741987-25-000010 · wk-form4_1766012033.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,307 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.61 to $29.20, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 11,500 | $3.64 | $41,860.00 |
DisclosureSEC source: 0001741987-25-000010 · wk-form4_1766012033.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F2 · balance_after: Due to a scrivener's error on the Reporting Person's Form 4 filed on November 5, 2025, the number of shares of common stock beneficially owned by the Reporting Person was inadvertently overstated by 18 shares. The corrected number of shares beneficially owned is reflected in this Form 4. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 22:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 17,250 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001741987-25-000008 · wk-form4_1762814517.xml · derivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,250 Underlying: Common Stock · 17,250 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F3 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 22:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 17,250 | $24.18 | $417,144.68 |
DisclosureSEC source: 0001741987-25-000008 · wk-form4_1762814517.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,325 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.79 to $24.4493, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 22:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 17,250 | $3.64 | $62,790.00 |
DisclosureSEC source: 0001741987-25-000008 · wk-form4_1762814517.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. Read SEC document |
| November 05, 2025 Filed Nov 5, 2025 23:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,864 | $23.72 | $91,643.26 |
DisclosureSEC source: 0001741987-25-000005 · wk-form4_1762387044.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,325 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.52 to $23.865, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 23:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 15 | $25.40 | $381.00 |
DisclosureSEC source: 0001741987-25-000005 · wk-form4_1762387044.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,189 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 23:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,607 | $24.71 | $64,425.23 |
DisclosureSEC source: 0001741987-25-000005 · wk-form4_1762387044.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,204 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.31 to $25.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 01:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,438 | $15.57 | $37,968.92 |
DisclosureSEC source: 0001787306-25-000130 · wk-form4_1755826361.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,811 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F3 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.43 to $15.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 19, 2025 Filed Aug 22, 2025 01:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,750 | $16.16 | $28,280.70 |
DisclosureSEC source: 0001787306-25-000130 · wk-form4_1755826361.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,249 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units. F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.87 to $16.73, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 21:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,847 | $14.03 | $53,988.41 |
DisclosureSEC source: 0001787306-25-000126 · wk-form4_1755032693.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,999 F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024 by the Reporting Person, with a plan end date of February 27, 2026. F1 · shares: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024 by the Reporting Person, with a plan end date of February 27, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.992 to $14.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 22:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,622 | $14.33 | $37,564.35 |
DisclosureSEC source: 0001787306-25-000118 · wk-form4_1754432935.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,846 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.965 to $14.675, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 14, 2025 Filed Jul 14, 2025 20:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 5,750 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · derivative · entry 6 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,500 Underlying: Common Stock · 5,750 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F4 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 14, 2025 Filed Jul 14, 2025 20:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 5,750 | $15.07 | $86,653.65 |
DisclosureSEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · nonDerivative · entry 4 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,468 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F3 · price: The transaction was executed in multiple trades in prices ranging from $15.00 to $15.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 14, 2025 Filed Jul 14, 2025 20:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 20:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · derivative · entry 5 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,250 Underlying: Common Stock · 23,000 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F4 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 20:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 23,000 | $15.05 | $346,046.50 |
DisclosureSEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,468 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.00 to $15.125, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 20:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:45 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,871 | $13.59 | $52,623.15 |
DisclosureSEC source: 0002065881-25-000007 · wk-form4_1746834341.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,468 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.50 to $13.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 02, 2025 Filed May 5, 2025 21:20 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,597 | $15.19 | $39,442.46 |
DisclosureSEC source: 0001787306-25-000084 · wk-form4_1746480007.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,339 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted on February 13, 2024. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.75 to $15.5519, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 12,242 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · derivative · entry 7 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,250 Underlying: Common Stock · 12,242 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 12,242 | $15.04 | $184,107.44 |
DisclosureSEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · nonDerivative · entry 5 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,936 F3 · shares: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. F5 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.1429, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 12,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · nonDerivative · entry 4 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 5,008 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · derivative · entry 6 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,492 Underlying: Common Stock · 5,008 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 5,008 | $15.10 | $75,631.32 |
DisclosureSEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,936 F3 · shares: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.34, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 5,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 44,153 | $14.97 | $660,771.72 |
DisclosureSEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,936 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.6545 to $15.35, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 00:44 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 954 | $13.28 | $12,673.03 |
DisclosureSEC source: 0001787306-25-000043 · wk-form4_1741135437.xml · nonDerivative · entry 4 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,089 F4 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs, granted on March 3, 2021. F5 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.28 to $13.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:44 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,819 | $13.03 | $36,734.67 |
DisclosureSEC source: 0001787306-25-000043 · wk-form4_1741135437.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,043 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs, granted on March 3, 2022 and March 2, 2023. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.6902 to $13.83, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:44 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 43,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001787306-25-000043 · wk-form4_1741135437.xml · derivative · entry 6 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2035-02-28 F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.